TY - JOUR
T1 - Yardstick for the medical management of chronic rhinosinusitis
AU - Borish, Larry
AU - Baroody, Fuad M.
AU - Kim, Margaret S.
AU - Lieberman, Jay A.
AU - Peters, Anju
AU - Stevens, Whitney W.
AU - Bernstein, Jonathan A.
N1 - Funding Information:
Disclosures: Dr Borish reports serving as consultant on the Role of Eosinophils in CRS Honorarium and receiving medical school grant for Expression of CD125 (IL-5R) on PMNs in chronic obstructive pulmonary disease (in which all funds go to the University of Virginia) from GlaxoSmithKline; serving as consultant Role of IL-4R in CRS, Asthma, and EOS Honorarium and receiving medical school grant for Attenuation of RV-Induced Asthma Exacerbations by Dupilumab (in which all funds go to the University of Virginia) from Regeneron; serving as consultant on the Role of TSLP in Asthma Honorarium for AstraZeneca; and receiving medical school grant for Low IgE as a Sentinel Event in CVID (in which all funds go to the University of Virginia) from CSL Behring. Dr Lieberman reports receiving honorarium as advisory board member from DBV and Novartis; receiving money to institution for contracted clinical research from DBV, Aimmune, and Regeneron; and serving as member of the Joint Task Force Practice Parameters and board member of the American Board of Allergy & Immunology. Dr Peters reports serving as consultant for AstraZeneca and GlaxoSmithKline and as research ad consultant for Optinose and Sanofi-Regeneron. Dr Stevens reports serving on the advisory boards for GlaxoSmithKline, Bristol Myers Squibb, and Genentech. Dr Bernstein reports serving as private investigator, consultant, and speaker for Sanofi-Regeneron, AstraZeneca, Novartis, and Genentech; speaker for Optinose and GlaxoSmithKline; and member of Joint Task Force Practice Parameters. The remaining authors have no conflicts of interest to report. Funding: The Yardstick series is funded by the American College of Allergy, Asthma, and Immunology.
Funding Information:
Funding: The Yardstick series is funded by the American College of Allergy, Asthma, and Immunology.
Publisher Copyright:
© 2021
PY - 2022/2
Y1 - 2022/2
N2 - Chronic rhinosinusitis (CRS) is an inflammatory condition of the paranasal sinuses defined by classic symptoms, imaging findings, or endoscopic findings. There are a growing number of emerging pharmacologic therapies being evaluated to treat patients with CRS, some of which have gained indication status in the United States. There have not been updated treatment guidelines published in the United States however since 2014. This document is meant to serve as an updated expert consensus document for the pharmacologic management of patients with CRS. We review available data focusing on prospective clinical trials on oral and intranasal corticosteroids, nasal irrigation, biologics, antibiotics, and allergy immunotherapy for CRS both with and without nasal polyposis, including specific therapies for aspirin-exacerbated respiratory disease–associated CRS and allergic fungal CRS. There are multiple options to treat CRS, and clinicians should be knowledgeable on the efficacy and risks of these available therapies. Allergists-immunologists now have various therapies available to treat patients with CRS.
AB - Chronic rhinosinusitis (CRS) is an inflammatory condition of the paranasal sinuses defined by classic symptoms, imaging findings, or endoscopic findings. There are a growing number of emerging pharmacologic therapies being evaluated to treat patients with CRS, some of which have gained indication status in the United States. There have not been updated treatment guidelines published in the United States however since 2014. This document is meant to serve as an updated expert consensus document for the pharmacologic management of patients with CRS. We review available data focusing on prospective clinical trials on oral and intranasal corticosteroids, nasal irrigation, biologics, antibiotics, and allergy immunotherapy for CRS both with and without nasal polyposis, including specific therapies for aspirin-exacerbated respiratory disease–associated CRS and allergic fungal CRS. There are multiple options to treat CRS, and clinicians should be knowledgeable on the efficacy and risks of these available therapies. Allergists-immunologists now have various therapies available to treat patients with CRS.
UR - http://www.scopus.com/inward/record.url?scp=85119532866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119532866&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2021.10.014
DO - 10.1016/j.anai.2021.10.014
M3 - Article
C2 - 34687874
AN - SCOPUS:85119532866
SN - 1081-1206
VL - 128
SP - 118
EP - 128
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 2
ER -